AAPGV (Ascentage Pharma Group Ltd) Gross Profit Margin

Official company branding of Ascentage Pharma Group International (AAPGV)

The gross margin level provided by the GURU.Markets platform for Ascentage Pharma Group (AAPGV) currently holds around 83.20. This trend reflects a critical dependence on external contractors for protein synthesis and clinical trials. Trade tensions between the US and China exacerbate these risks, slowing down global drug certification. Meanwhile, unique patents for apoptosis inhibitors create a powerful defensive barrier against new market entrants.

AAPGV - Ascentage Return on Gross Profit over the range 01/25/2025 - 11/20/2026

Financial and market metric breakdowns for Ascentage (AAPGV)

Fundamental valuation:AAPGV Ascentage Pharma Group Ltd
Manufactured product of Ascentage Pharma Group Ltd

Gross margin determines production efficiency by measuring the share of profit after deducting direct costs from total revenue. For Ascentage Pharma Group (AAPGV), this metric reflects the ability to maintain high drug pricing amidst fierce global competition and patent risks. By analyzing the current gross margin level, an investor can assess the business's resilience to geopolitical pressure and the potential loss of access to premium markets.

Key competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Profitability RVMD|Return on Gross Profit AAPG (Ascentage)|Return on Gross Profit cgoncology.com CGON|UroGen Pharma - Return on Gross Profit|Gross Profit Rate BCAX|PSNL - Gross Profitability|Return on Sales by Gross Profit Erasca Oncology ERAS|delcath.com (DCTH) - Gross Profitability|Y-mAbs Therapeutics - Gross Profit Rate|AURA (Aura Biosciences Inc) - Gross Margin|Gross Profit Margin candeltx.com CADL|Gross Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Gross Profit Rate|Gross Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Gross Profitability|TuHURA Biosciences Inc. - Gross Margin|TARA - Gross Margin|FATE (Fate Therapeutics) - Return on Gross Profit|Return on Gross Profit Aadi Bioscience, Inc.|Return on Gross Profit TCRX|Gross Profitability CSBR|Gross Margin XBIT|Return on Sales by Gross Profit CEL-SCI Corp.|Gross Profitability ostherapies.com OSTX|RADX: Gross Return on Sales|ARTV: Return on Gross Profit|ANL (Adlai Nortye) - Gross Return on Sales|Veru (VERU) - Gross Profitability|Return on Gross Profit Tempest Therapeutics Inc|Gross Profitability Xilio Therapeutics|Gross Return on Sales RENB (Renovaro Inc.)|Gross Profitability Mural Oncology PLC (MURA)|Gross Margin Kairos Pharma (KAPA)|Gross Profitability onkuretherapeutics.com OKUR|GDTC: Gross Return on Sales|CRIS: Return on Gross Profit|apollomicsinc.com (APLM) - Return on Gross Profit|THAR: Gross Margin|Return on Gross Profit Advanced Biomed Inc.|Return on Gross Profit GNPX|Gross Return on Sales CLDI (Calidi Biotherapeutics)|Gross Margin SBFM|Xenetic Biosciences, Inc. - Gross Return on Sales|Gross Profitability Salarius Pharmaceuticals SLRX|Gross Margin purple-biotech.com PPBT|AONC - Gross Profitability|BGNE: Gross Profitability|CKPT: Gross Margin|Elevation Oncology - Gross Profit Rate|ICAD (iCAD) - Gross Margin|IKNA: Gross Profit Rate|Gross Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Gross Profit Rate|Gross Profitability MorphoSys Corporation MOR|NAYA: Gross Return on Sales